Lilly/Alkermes Inhaled Insulin To Enter Late-Stage Development
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies are finalizing plans for Phase II and Phase III trials following successful Phase II study in type 1 diabetes and completion of manufacturing scale-up and inhaler device development. The partnership is Lilly’s third stab at non-injectable insulin development.